Pharmaceutical industry acquisition advised by legal firms Khaitan, SAM, and AZB, valued at a substantial $1.4 billion in India.
Torrent Pharmaceuticals Acquires Major Stake in JB Chemicals in a Value-Accretive Deal
Torrent Pharmaceuticals, a prominent player in the Indian pharmaceutical industry, has announced the acquisition of a 46.4% controlling stake in JB Chemicals and Pharmaceuticals from KKR for approximately $1.4 billion (₹11,917 crore). This strategically significant transaction is set to reshape Torrent’s market presence in India and abroad.
Key Details of the Acquisition
The acquisition involves purchasing a 46.4% controlling share at ₹1,600 per share, with an open offer to acquire up to an additional 26% of shares at a premium open offer price of ₹1,639.18 per share. The full acquisition and integration plan values JB Chemicals at an equity valuation of around ₹25,689 crore on a fully diluted basis. This equates to an enterprise value of about ₹26,630 crore ($3.3 billion) for JB Chemicals.
The acquisition process will be phased, starting with the initial stake acquisition, followed by a mandatory open offer to public shareholders, and culminating in a merger of JB Chemicals into Torrent Pharmaceuticals under regulatory approvals.
Portfolio Expansion and Market Impact
The acquisition significantly broadens Torrent’s offerings, adding JB Chemicals’ strengths in ophthalmology, IVF, nephrology, anti-parasitics, and lozenges manufacturing (CDMO segment). Torrent, which already dominates the cardiac, gastroenterology, and CNS sectors, stands to benefit from the largely complementary portfolios.
Post-merger, the combined entity is expected to leapfrog and become the 5th largest pharmaceutical company in India, with a market share increased from 3.6% to 4.8%. The acquisition also expands Torrent’s reach into emerging markets like South Africa and Russia, complementing its footprint in the US and Brazil.
Strategic Leap into CDMO
JB Chemicals’ Contract Development and Manufacturing Organization capabilities, including a global client base and cost-plus pricing model, offer high-margin, scalable growth avenues that are new to Torrent.
Implications of the Transaction
The acquisition enables Torrent to diversify and deepen its chronic therapy portfolio while gaining entry into niche and underpenetrated therapeutic areas, increasing future growth prospects. The limited overlap minimizes internal product cannibalization, preserving revenue stability and enhancing complementary market reach.
Gaining a controlling stake in a company with strong international operations boosts Torrent’s global competitiveness and export potential. This transaction is one of the largest pharma sector deals in recent years in India, marking a significant consolidation in a fragmented market and indicating strength in strategic inorganic growth moves.
The complex integration and merger process includes execution risks but also promises substantial synergies, broader market access, and enhanced R&D capabilities aligned for international markets and evolving therapy segments.
Background
Torrent Pharmaceuticals offers drugs for cancer, infections, and diabetes. The transaction, which is the largest in India’s pharmaceutical industry this year, implies a total equity valuation of $3.01 billion for JB Chemicals according to Reuters. It is the second-largest ever in India’s pharmaceutical industry, after Sun Pharmaceuticals acquired Ranbaxy for $4 billion about a decade ago.
Torrent Pharmaceuticals competes with Mankind Pharma in India. Vaidhyanadhan Iyer led the AZB team for JB Pharma's board of directors, while Khaitan & Co advised Torrent Pharmaceuticals on the agreement. Shardul Amarchand Mangaldas acted for the sellers in the same agreement. Bhavik Narsana and Mehul Shah led the Khaitan team for Torrent Pharmaceuticals, with Arindam Ghosh and Anshuman Sakle providing assistance. Jeet Chaudhuri was a part of the AZB team for JB Pharma's board of directors.
Torrent Pharmaceuticals' biggest market by revenue is India. The company has benefited from steady demand for its speciality and chronic illness drugs.
- The acquisition of JB Chemicals by Torrent Pharmaceuticals is a strategic move aimed at strengthening Torrent's financial standing and market presence, both in India and abroad.
- With the acquisition of JB Chemicals, Torrent Pharmaceuticals expects to diversify and expand its portfolio, particularly in the Contract Development and Manufacturing Organization (CDMO) segment, providing high-margin, scalable growth opportunities.
